Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT03302403
What this trial is testing

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Who this might be right for
B Cell LymphomaB Cell LeukemiaMyeloma+3 more
Kang YU 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03642626
What this trial is testing

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaLarge B-cell Lymphoma
Masonic Cancer Center, University of Minnesota 150
Early research (Phase 1)UnknownNCT04007978
What this trial is testing

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 50
Very early researchUnknownNCT06574958
What this trial is testing

Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

Who this might be right for
ORR,OS,PFS
The Second Hospital of Shandong University 10
Early research (Phase 1)Looking for participantsNCT07266181
What this trial is testing

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

Who this might be right for
Refractory Membranous Nephropathy
The First Affiliated Hospital of Air Force Medicial University 5
Very early researchNot Yet RecruitingNCT07392528
What this trial is testing

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Who this might be right for
Neuromyelitis Optica Spectrum DisordersMultiple SclerosisMyasthenia Gravis
Tianjin Huanhu Hospital 15
Early research (Phase 1)Active Not RecruitingNCT04732845
What this trial is testing

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia
Benjamin Tomlinson 18
Early research (Phase 1)Active Not RecruitingNCT03602157
What this trial is testing

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Who this might be right for
LymphomaImmune System DiseasesImmunoproliferative Disorders+10 more
UNC Lineberger Comprehensive Cancer Center 43
Early research (Phase 1)Looking for participantsNCT06313957
What this trial is testing

LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute 42
Testing effectiveness (Phase 2)Study completedNCT03310619
What this trial is testing

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
Celgene 62
Early research (Phase 1)Not Yet RecruitingNCT07553793
What this trial is testing

Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients

Who this might be right for
Pancreatic CancerAdvanced Stage Cancer
Peking Union Medical College Hospital 18
Large-scale testing (Phase 3)UnknownNCT04257175
What this trial is testing

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Who this might be right for
Acute Myeloid Leukemia
Sheba Medical Center 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04429451
What this trial is testing

PSMA-specific CAR-T Cell Therapy

Who this might be right for
PSMA Positive Tumors or Tumor Tissues
Shenzhen Geno-Immune Medical Institute 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07825389
What this trial is testing

C-CAR168 in Participants With Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AbelZeta Inc. 119
Not applicableNot Yet RecruitingNCT07577583
What this trial is testing

Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel

Who this might be right for
B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc. 32
Testing effectiveness (Phase 2)Looking for participantsNCT06880913
What this trial is testing

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Who this might be right for
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Early research (Phase 1)Looking for participantsNCT05391490
What this trial is testing

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Who this might be right for
Blood Cancer
University College, London 12
Early research (Phase 1)Looking for participantsNCT05836896
What this trial is testing

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Who this might be right for
NeoplasmsRelapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)+2 more
Technische Universität Dresden 16
Early research (Phase 1)Looking for participantsNCT04715191
What this trial is testing

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Who this might be right for
Liver CancerRhabdomyosarcomaMalignant Rhabdoid Tumor+3 more
Baylor College of Medicine 24
Next Page